A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Phase 2 Unknown 66 enrolled Shanghai Miracogen Inc.

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.

Timeline

Start: 2021-05-13
Primary completion: 2023-02
Completion: 2023-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TRASTUZUMAB VEDOTIN	Unknown	2.6 mg/kg	Intravenous

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Summary

Timeline

Drugs

Indications